Browse News
Filter News
Found 486,036 articles
-
The particular areas where sales jobs will be thinned is primary care, disease-focused endocrinology and hospital chronic care.
-
Celgene is scrapping a late-stage Crohn's disease drug it acquired in a $710M deal three years ago following an interim data analysis.
-
Allergan is a good example of how many mergers and acquisitions over a very short period of time created a large, international company.
-
CAR-T therapy is the big thing right now, with this week's approval of Gilead Yescarta and the recent approval of Novartis' Kymriah.
-
DURECT's Posimir (SABER - Bupivacaine) for post-surgical pain failed its Phase III clinical trial.
-
Analysts with SunTrust Robinson Humphrey recently published a research report that looked at a number of large-cap pharma companies.
-
Two factors have increased speculation that Smith & Nephew may be ready for a takeover.
-
Universal Cells will get $9 million upfront and is eligible to regulatory milestones payments of up to $115 million, as well as royalties.
-
The way the university handled it violated state law, according to state officials.
-
The company was among dozens of firms worldwide hit in the June 27 attack.
-
Final Results of Albireo's Phase II Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017
10/20/2017
A4250 reduced serum bile acids and improved pruritus in most patients, exhibited a favorable overall tolerability profile .
-
Nexus Pharmaceuticals Receives FDA Approval for Procainamide HCL Injection, USP
10/20/2017
Nexus Pharma announced today the immediate availability in the United States of Procainamide HCL Injection, USP.
-
AzurRx BioPharma and Mayoly Spindler Announce MS1819-SD Investigational Medicinal Product Dossier...
10/20/2017
This IMPD has been submitted through the EMA clinical trial portal for approval prior to opening of clinical centers in France. -
Spero Therapeutics Initiates Clinical Program for Oral Carbapenem SPR994
10/20/2017
Spero plans for a rapid development approach with SPR994.
-
VBL Therapeutics Announces Orphan Drug Designation for VB-111 in Europe
10/20/2017
The EMA has designated ofranergene obadenovec (VB-111) as an 'orphan medicinal product' for the treatment of ovarian cancer.
-
Omeros Reports Successful OMS721 Treatment of Patient With Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-Versus-Host Disease
10/20/2017
The results may expand target for Omeros' planned phase 3 program in HCT-TMA.
-
Shionogi Release: Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
10/20/2017
Shionogi announced it will present positive efficacy and safety results from a global Phase 3 study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C.
-
RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
10/20/2017
The Orphan Drug designation allows RedHill to benefit from various development incentives to develop MESUPRON for this indication.
-
Spring Bank Pharmaceuticals Announces Additional Inarigivir (Formerly SB 9200) Results From the ACHIEVE Trial in HBV Patients at AASLD Conference
10/20/2017
The Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial.
-
AcelRx's DSUVIA Clinical Trial Results Selected as a Top Abstract for Oral Presentation at ASA's Annual Meeting - ANESTHESIOLOGY 2017
10/20/2017
AcelRx today announced its clinical data presentation on the safety and efficacy of DSUVIA(sufentanil sublingual tablet), 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists'(ASA) ANESTHESIOLOGY 2017 Annual Meeting.